<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The availability of low molecular weight <z:chebi fb="5" ids="28304">heparin</z:chebi> (LMWH), with associated ease of home delivery and enhanced efficacy and safety, has rendered the long-term outpatient use of LMWH feasible </plain></SENT>
<SENT sid="1" pm="."><plain>Although <z:chebi fb="8" ids="10033">warfarin</z:chebi> is usually used for long-term secondary prevention, it is not the drug of choice for a variety of conditions such as antiphospholipid <z:mp ids='MP_0005048'>thrombosis</z:mp> syndrome, sticky platelet syndrome, and patients with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> and other medical conditions who have failed adequate <z:chebi fb="8" ids="10033">warfarin</z:chebi> doses </plain></SENT>
<SENT sid="2" pm="."><plain>We assessed the long-term efficacy and safety of outpatient dalteparin in a series of patients with conditions associated with prior <z:chebi fb="8" ids="10033">warfarin</z:chebi> failure or potential to <z:chebi fb="8" ids="10033">warfarin</z:chebi> therapy (<z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>The results of this study, detailed herein, demonstrate that long-term dalteparin is highly effective and safe when used as long-term therapy for secondary prevention in selected prothrombotic disorders </plain></SENT>
</text></document>